Inflection Point Acquisition Corp. IV Reports Q3 2025 Net Income of $83,694, Plans Merger with Merlin Labs

Inflection Point Acquisition Corp. IV, formerly known as Bleichroeder Acquisition Corp. I, reported its financial results for the third quarter of 2025, revealing a net income of $83,694 for the three months ended September 30, 2025, compared to a net loss of $47,447 for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net income of $4,809,256, significantly up from a loss of $77,427 during the period from June 24, 2024, through September 30, 2024. The increase in net income was primarily driven by interest earned on investments held in the Trust Account, which amounted to $2,685,470 for the quarter and $7,973,982 for the nine-month period.

The company’s total assets as of September 30, 2025, were reported at $261,074,868, an increase from $254,219,522 at the end of 2024. This growth was largely attributed to the investments held in the Trust Account, which rose to $259,730,180 from $251,756,198. However, the company also experienced a rise in current liabilities, which increased to $3,124,541 from $1,078,451, primarily due to accrued expenses and other operational costs.

In terms of strategic developments, Inflection Point Acquisition Corp. IV is in the process of executing a Business Combination Agreement with Merlin Labs, Inc., which was signed on August 13, 2025. This agreement outlines the merger of the two entities, with the intention of continuing operations under the name Merlin Labs, Inc. The company is also planning to change its jurisdiction of incorporation from the Cayman Islands to Delaware, pending shareholder approval. This move is part of a broader strategy to facilitate the Business Combination and enhance operational flexibility.

Operationally, the company has not yet commenced any significant business activities, as it was formed primarily for the purpose of effecting a Business Combination. As of September 30, 2025, the company had 25,425,000 Class A ordinary shares and 8,333,333 Class B ordinary shares outstanding. The company’s management has indicated that it may need to raise additional capital to meet working capital needs and complete the Business Combination, which is currently set to occur before the end of the Combination Period on November 6, 2026. The company has expressed uncertainty regarding its ability to secure additional financing, which could impact its operational plans and overall viability.

Looking ahead, the company remains focused on finalizing the Business Combination with Merlin Labs and is actively seeking to address its liquidity needs. The management team has acknowledged the potential risks associated with the completion of the Business Combination, including market conditions and regulatory approvals. The company’s future performance will largely depend on the successful execution of this merger and its ability to navigate the complexities of the current market environment.